Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.52 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.52 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.52 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684603 | 0.88 | NPC1 (0.65) | NPC1RAB9ATDP1CYP2A6ALDH1A1 | |
| SCHEMBL23188 | 0.88 | NPC1 (0.65) | NPC1RAB9ATDP1CYP2A6ALDH1A1 | |
| SCHEMBL29399968 | 0.88 | NPC1 (0.65) | NPC1RAB9ATDP1CYP2A6ALDH1A1 | |
| SCHEMBL32688276 | 0.87 | ABL1 (0.58) | ERN1NPC1RAB9ATDP1HDAC4 | |
| SCHEMBL2581063 | 0.87 | DRD1 (0.64) | ERN1HDAC4HDAC8CYP2A6CYP1A1 | |
| SCHEMBL1977748 | 0.87 | ABL1 (0.58) | ERN1NPC1RAB9ATDP1HDAC4 | |
| SCHEMBL29998099 | 0.86 | NPC1 (0.63) | NPC1RAB9ATDP1CYP2A6ALDH1A1 | |
| Ethane SCHEMBL1494210 | 0.86 | NPC1 (0.63) | NPC1RAB9ATDP1CYP2A6ALDH1A1 | |
| SCHEMBL4510797 | 0.84 | ABL1 (0.54) | ERN1NPC1RAB9ATDP1HDAC4 | |
| SCHEMBL16180188 | 0.84 | CYP11B1 (0.49) | ERN1NPC1RAB9ATDP1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4257583-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Institute of Science and Technology (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20170226317-A1 | POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-2986607-B1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9527867-B2 | Antibacterial biaromatic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-12-27 | — | — | US | disclosed |
| US-20160075722-A1 | Antibacterial Biaromatic Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-17 | — | — | US | disclosed |
| EP-2986607-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014170821-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-23 | — | — | WO | disclosed |
| WO-2011135303-A2 | UBIQUITINATION MODULATORS | ITI SCOTLAND LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011135303-A2 | UBIQUITINATION MODULATORS | ITI SCOTLAND LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1979324-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | ERN1 4004/4885NPC1 512/4885RAB9A 1387/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ERN1 1882/4885NPC1 4727/4885RAB9A 944/4885 |
| US-20160075722-A1 | Antibacterial Biaromatic Derivatives | CYC1, C5, CYCS | ERN1 480/4885NPC1 2130/4885RAB9A 3081/4885 |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CD274, PDCD1, PDCD1LG2 | ERN1 1567/4885NPC1 1942/4885RAB9A 2168/4885 |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | ERN1 3221/4885NPC1 247/4885RAB9A 1556/4885 |
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | HTR7, TPH1, HTR2C | ERN1 4783/4885NPC1 3998/4885RAB9A 1956/4885 |
| US-20170226317-A1 | POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE | NBAS, SSB, BIRC5 | ERN1 4128/4885NPC1 2604/4885RAB9A 1276/4885 |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | ERN1 3221/4885NPC1 247/4885RAB9A 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.